Form 6-K Galmed Pharmaceuticals For: Aug 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Galmed Pharma (GLMD) Misses Q2 EPS by 4c
August 3, 2016 8:51 AM EDTGalmed Pharma (NASDAQ: GLMD) reported Q2 EPS of ($0.39), $0.04 worse than the analyst estimate of ($0.35).
For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.
... More


